YOU ARE HERE > Home > News > The French Pharma Market

The French Pharma Market

Description

 “The French Pharma Market – 2016-2022 prospects” report provides a description of the French healthcare system from a legal, organizational and economic point of view.  

This new edition offers in a clear, specific and concise format:

 

Product details

Soft copy: 233 pages (PowerPoint)
Language: English
Price: English €5,000 (excl. tax)

Consult short version

 

  

Contents

Introduction

·         International healthcare expenditure

·         Global pharma market (2016 – 2022)

 

Section 1. The French healthcare system

1.1. Key healthcare stakeholders

·         Mapping of key stakeholders

·         Policy makers and regulators

·         Overall reimbursement and pricing processes

·         Parliament and Ministry of Health

·         ANSM

·         HAS (CEESP – CT) 

·         CEPS

·         National and regional market access in a nutshell 

·         Community hospitable territory (GHT)

·         Market access to new drugs – International comparisons

·         National health insurance fund instances

·         Complementary health cover organizations

·         Regional health agencies

·         Healthcare professionals and facilities

·         Hospital financing systems

·         Drug distribution channels

·         Economy of retail pharmacies

·         Voluntary trade organizations

·         On-line sales of pharmaceutical products

·         Patients’ confidence in drugs

 

1.2. Recent reforms 

·         The French Sunshine Act

·         New regulations towards generics and biosimilars

·         Measures to limit the financial impact of expensive drugs

·         LFSS 2015 key articles regarding drugs and pharma companies

·         LFSS 2016 key articles regarding drugs and pharma companies

·         Health System Modernization Act (incl. GHT)

·         LFSS 2017 key articles regarding drugs and pharma companies

·         LFSS 2017 main savings measures

·         The 11 compulsory vaccines law project

 

1.3. Healthcare expenditure 

·         Relation between healthcare expenditure and GDP

·         Supply, consumption and funding of healthcare

·         Social Security & national health insurance fund balances

·         ONDAM

·         Hospital expenses

·         Expenditure by age group

·         Breakdown of healthcare expenditure and coverage

·         Evolution of the reimbursement system

·         Price cuts and economic impact

·         Main governmental measures relative to generics


Section 2. The French pharmaceutical market

2.1. Evolution of drug sales

·         Classification of pharmaceutical products in France

·         Evolution of drug sales by segment (2012 – 2016)

·         Hospital drug market dynamics (2012 – 2016)

·         Evolution of drug sales by reimbursement rate (2011 – 2016)

·         Top 10 therapeutic areas retail & hospital (2016)

·         Top 10 products retail & hospital

·         Sales of drugs on top “T2A” (2012 – 2016)

·         The four status of “copies” in France

·         Analysis of the regulation regarding the creation of generics group

·         Molecules having lost their patent protection in 2016

·         Evolution of reimbursable generics in the retail market 

·         Evolution of reimbursable generics market share in the retail market

·         Evolution of reimbursable generics penetration in the retail market 

·         Public objectives of prescription within the generics Directory (2016)

·         Savings generated by generics (2007 – 2016)

·         Biosimilar drug market in France (2016)

·         Evolution of the biosimilar market (2007 – 2016)

·         OTC market size and structure (2016)

·         Top 10 therapeutic areas in the OTC market (2016)

·         Top 10 brands and umbrella brands in the OTC market (2016)

·         Main barriers to the development of the OCT market in France

 

2.2. Evolution of pharma companies sales

·         Top 10 pharma companies retail and hospital market

·         Top 10 pharma companies on the retail market

·         Top 10 pharma companies on the hospital market

·         Top 10 generics companies on the retail market

·         Top 10 generics companies on the hospital market

·         Top 10 generics companies on the OTC market

 

2.3. Future market trends

·         Evolution of drug sales by segment (2012 – 2016 – 2022)

·         Factors driving the evolution of drug sales by market segment (2016 – 2022)

·         Drivers & limiters of biosimilars use by key stakeholders

·         Determinants to biosimilar sales forecasts

·         Evolution of the biosimilars market in France (2016)

·         Market value of classes/INN impacted by biosimilars (2016 – 2022)

·         Originators and biosimilars’ sales forecasts – Retail and hospital markets (2016 – 2022)

 

Section 3. Strategic priorities for pharma companies

3.1. Introduction (7 Ps)
3.2. Policy makers and Payers

·         2016-2022 trends

·         Driving factors

·         Implications

·         Strategic priorities


3.3. Physicians

·         2016-2022 trends

·         Driving factors

·         Implications

·         Strategic priorities

 

3.4. Pharmacists

·         Levers and solutions to improve the economy of pharmacies

·         2016-2022 trends

·         Driving factors

·         Implications

·         Strategic priorities

 

3.5. Patients and PAGs

·         2016-2022 trends

·         Driving factors

·         Implications

·         Strategic priorities

 

3.6. Pharma competitors

·         2016-2022 trends

·         Driving factors

·         Implications

·         Strategic priorities 


Conclusion

 

Glossary